PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 7, 2026Open Forum Infectious Diseases0 citationsOpen Access

Real-world effectiveness of adjuvanted RSVPreF3 vaccine in preventing RSV-associated lower respiratory tract disease hospitalization in adults ≥60 years of age: early results from a test-negative design analysis

View Full Paper
JKJennifer H KuLQLei QianLSLina S. Sy

Key Points

  • This research aims to evaluate the effectiveness of the adjuvanted RSVPreF3 vaccine in preventing RSV-related hospitalizations in adults aged 60 and older.
  • Test-negative design analysis conducted from Dec 2023 to Feb 2025.
  • Assessing adults aged ≥60 years with laboratory-confirmed RSV-related hospitalizations.
  • Evaluating vaccine effectiveness within the season.
  • Overall vaccine effectiveness (VE) estimated at 82.3%.
  • VE for subgroups ranged from 81.0% to 92.1%.
  • Effective protection noted particularly among individuals at increased risk of severe RSV disease.

Abstract

Abstract In a test-negative design, we estimated within-season vaccine effectiveness (VE) of adjuvanted RSVPreF3 against laboratory-confirmed respiratory syncytial virus (RSV)-lower respiratory tract disease-associated hospitalizations in adults ≥60 years during Dec2023–Feb2025. Results showed 82.3% overall VE and 81.0–92.1% VE across subgroups, including those at increased risk of severe RSV disease.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ku et al. (2026) studied this question.

synapsesocial.com/papers/69fc2c4b8b49bacb8b347cf4https://doi.org/10.1093/ofid/ofag279
Ask AI
Helpful
Bookmark
Share
View Full Paper